Home
Guidelines
Pathogens
Antimicrobials
Caspofungin 70mg IV x 1 dose, followed by 50mg IV daily
OR
Fluconazole 800mg PO/IV x 1 dose, followed by 400mg PO/IV daily
Empiric fluconazole should only be used in selected patients who are not critically ill and who are considered unlikely to have a fluconazole-resistant Candida species.
Testing for azole susceptibility is performed for invasive Candida isolates.
This test is performed out of province, so results are delayed.
Transition from an echinocandin to fluconazole is recommended for patients who are clinically stable and have negative repeat blood cultures following initiation of antifungal therapy.
Recommended duration of therapy for candidemia without obvious metastatic complications is for 2 weeks after documented clearance of Candida species from the bloodstream, and resolution of symptoms attributable to candidemia.
Duration of therapy in the setting of metastatic foci should be determined in collaboration with the Infectious Diseases team.
